Added to YB: 2026-02-09
Pitch date: 2026-02-05
NOVO-B.CO [neutral]
Novo Nordisk A/S
-13.16%
current return
Author Info
Lux Opes Research covers European companies. Lots of them. Sign up for the newsletter.
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products.
Market Cap
DKK 1.1T
Pitch Price
DKK 272.82
Price Target
N/A
Dividend
4.94%
EV/EBITDA
7.46
P/E
10.29
EV/Sales
3.74
Sector
Pharmaceuticals
Category
turnaround
Novo Nordisk (NOVOB Denmark): ouch… the US resets the near-term care
NOVO-B.CO (earnings): Q4 beat on sales (DKK 79.1bn, +3% vs est) but margins disappointed at 40.1%. US struggles continue - diabetes -7%, obesity -4% on pricing pressure. 2026 guidance warns 5-13% decline in sales/EBIT as MFN pricing, semaglutide LOE, competition bite. Transition year ahead.
Read full article (2 min)